Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, double blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of a single treatment of Botox (Botulinum Toxin Type A) purified neurotoxin complex injected into the prostate for the treatment of lower urinary tract symptoms in patients due to benign prostatic hyperplasia. [Studio dose-risposta multicentrico, in doppio cieco, randomizzato, controllato con placebo per valutare la tollerabilita` e la sicurezza di una singola somministrazione di BOTOX (tossina botulinica di tipo A), complesso di neurotossina purificata iniettato nella prostata per il trattamento dei sintomi del tratto urinario inferiore in pazienti con Iperplasia Prostatica Benigna]

Next Previous
Trial Profile

A multicenter, double blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of a single treatment of Botox (Botulinum Toxin Type A) purified neurotoxin complex injected into the prostate for the treatment of lower urinary tract symptoms in patients due to benign prostatic hyperplasia. [Studio dose-risposta multicentrico, in doppio cieco, randomizzato, controllato con placebo per valutare la tollerabilita` e la sicurezza di una singola somministrazione di BOTOX (tossina botulinica di tipo A), complesso di neurotossina purificata iniettato nella prostata per il trattamento dei sintomi del tratto urinario inferiore in pazienti con Iperplasia Prostatica Benigna]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergan

Most Recent Events

  • 17 May 2012 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
  • 17 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 27 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top